Compugen CGEN 深 滬
已收盤 09-26 16:00:00 美东时间
1.38
0.000
0.00%
華盛通- 最 高1.40
- 今 開1.40
- 成交量 8.85万股
- 最 低 1.37
- 昨 收 1.38
- 總市值 1.29亿
- 52周最高 2.66
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.13
- 委 比 -34.74%
- 總股本 9353.54万
- 歷史最高 19.90
- 量 比 0.28
- 振 幅 2.17%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Compugen to Present Research at the Single Cell Genomics 2025 Conference
HOLON, ISRAEL, Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discover...
09-08 19:00
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Compugen Initiates Global Trial for COM701 in Ovarian Cancer
Compugen ( ($CGEN) ) has shared an update. On July 21, 2025, Compugen Ltd. anno...
07-21 19:28
Compugen’s Q1 2025: Clinical Progress and Financial Stability
Compugen ( ($CGEN) ) has released its Q1 earnings. Here is a breakdown of the i...
05-20 11:56
Compugen GAAP EPS of -$0.08, revenue of $2.3M
Compugen press release (NASDAQ:CGEN): Q1 GAAP EPS of -$0.08. Revenue of $2.3M (-11.5% Y/Y). Cash: As of March 31, 2025, Compugen had approximately $103.7 million in cash, cash equivalents, short-term ...
05-19 19:13
Compugen Q1 EPS $(0.08) Misses $(0.06) Estimate, Sales $2.28M Miss $3.70M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The company reported
05-19 19:01
Earnings Scheduled For May 19, 2025
Companies Reporting Before The Bell • Global Ship Lease (NYSE:GSL) is estimated...
05-19 16:32
Catalyst Watch: Tariff drama, big banks report earnings, Walmart meeting, and the CPI print
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Saturday - April 5...
04-05 03:00
BeiGene slips on decision to halt lung cancer program
BeiGene (BGNE) ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung ...
04-03 18:58
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability
Compugen ( ($CGEN) ) has released its Q4 earnings. Here is a breakdown of the i...
03-05 11:56
